| Formulary Chapter 7: Obstetrics, Gynaecology, and urinary-tract disorders - Full Chapter
|
| Notes: |
Chapter review date: |
|
| Details... |
| 07.03.01 |
Combined hormonal contraceptives |
|
|
 |
RBCH: With the exception of emergency contraception and Mirena devices, contraceptives are not supplied.
Soya may be included as an excipient in medicines. How it is listed as an excipient may vary. Further information regarding how it is named would be available through the regional medicines information service at Southampton if required |
|
Ethinylestradiol 20 mcg / norethisterone 1mg
|
First Choice
 
|
Ethinylestradiol 20 mcg / norethisterone 1mg
Prescribe by brand
Loestrin 20®
* 30th September 2019
The manufacturer advises that this product has been discontinued.
The Faculty of Sexual and Reproductive Healthcare recommend that a 30mcgEE/NET COC (Ovranette®/Microgynon®/Rigevidon®) can be considered first line CHC. If this is not tolerated, there is not clear evidence to inform a recommendation favouring any one 20/30mcg EE COC over any other based on progestogen content.
|
|
|
Ethinylestradiol 20mcg / desogestrel 150mcg
|
First Choice
|
Ethinylestradiol 20mcg / desogestrel 150mcg
Prescribe by brand
Mercilon® 150microgram/20microgram tablets
Bimizza® 150microgram/20microgram tablets
Gedarel® 20microgram/150microgram tablets
Munalea® 150microgram/20microgram tablets
|
|
|
Ethinylestradiol 30 micrograms/ Norethisterone acetate 1.5mg
|
First Choice
|
Ethinylestradiol 30 micrograms/ Norethisterone acetate 1.5mg
Prescribe by brand
Loestrin 30®
* 30th September 2019
The manufacturer advises that this product has been discontinued.
The Faculty of Sexual and Reproductive Healthcare recommend that a 30mcgEE/NET COC (Ovranette®/Microgynon®/Rigevidon®) can be considered first line CHC. If this is not tolerated, there is not clear evidence to inform a recommendation favouring any one 20/30mcg EE COC over any other based on progestogen content.
|
|
|
Ethinylestradiol 30 micrograms/gestodene 75 micrograms
|
First Choice
|
Ethinylestradiol 30 micrograms/gestodene 75 micrograms
Prescribe by brand
Femodene® tablets
Aidulan® 30microgram/75microgram tablets
Katya® 30/75 tablets
Millinette® 30microgram/75microgram tablets
Sofiperla® 75microgram/30microgram tablets
|
|
|
Ethinylestradiol 30mcg / levonorgestrel 150mcg
|
First Choice
|
Ethinylestradiol 30mcg / levonorgestrel 150mcg
Prescribe by brand
Microgynon 30® tablets
Elevin® 150microgram/30microgram
Leandra®30microgram/150microgram tablets
Levest® 150/30 tablets
Maexeni® 150microgram/30microgram tablets
Ovranette® 150microgram/30microgram tablets
Rigevidon® tablets
|
|
|
Ethinylestradiol 35 micrograms/Norgestimate 250 micrograms
|
First Choice
|
Ethinylestradiol 35 micrograms/Norgestimate 250 micrograms
Prescribe by brand
Cilique® 250microgram/35microgram tablets
Lizinna® 250microgram/35microgram tablets
Cilest® - Now discontinued.
|
|
|
Ethinylestradiol 30 micrograms/drospirenone 3 mg
|
Second Choice
|
Ethinylestradiol 30 micrograms/drospirenone 3 mg.
Use in accordance with locally agreed guideline. Not for first-line use.
Prescribe by brand
Yasmin®
Dretine® 0.03mg/3mg tablets
Lucette® 0.03mg/3mg tablets
Yacella® 0.03mg/3mg tablets
Yiznell® 0.03mg/3mg tablets
|
 Guidance for prescribing of Yasmin®
|
SyreniRing ®
|
Second Choice
|
|
|
|
Combined Hormonal Contraceptives (Evra®)
|
Formulary
|
Transdermal combined contraceptive patch, which contains norelgestromin and ethinyloestradiol.
Refer to local guidance.
DCHFT: On local formulary.
|
Evra® local guidance on suitable patients
|
NuvaRing®
|
Formulary
|
To be initiated under specialist advice
Vaginal ring, releasing ethinylestradiol approx. 15 micrograms/24 hours and etonogestrel approx. 120 micrograms/24 hours,
|
|
|
|
|
|
|
|
|
| 07.03.01.02 |
Co-cyprindiol |
|
|
| 07.03.01.03 |
Phased formulations – standard dose 30 micogram oestrogen |
|
|
| 07.03.01.04 |
Low dose oestrogen – 20 microgram ethinylestradiol |
|
|
| 07.03.01.05 |
Transdermal (standard strength) |
|
|
| 07.03.01.06 |
Vaginal rings (low strength |
|
|
| 07.03.01.07 |
Copper intra-uterine devices |
|
|
| .... |
| Non Formulary Items |
Combined Hormonal Contraceptives (BiNovum®)
|
Non Formulary
|
|
|
|
Combined Hormonal Contraceptives (Femodene® ED)
|
Non Formulary
|
|
|
|
Combined Hormonal Contraceptives (Levest®)
|
Non Formulary
|
|
|
|
Combined Hormonal Contraceptives (Logynon ED®)
|
Non Formulary
|
|
|
|
Combined Hormonal Contraceptives (Microgynon 30 ED®)
|
Non Formulary
|
|
|
|
Combined Hormonal Contraceptives (Minulet®)
|
Non Formulary
|
|
|
|
Combined Hormonal Contraceptives (Norinyl-1®)
|
Non Formulary
|
|
|
|
Combined Hormonal Contraceptives (Synphase®)
|
Non Formulary
|
|
|
|
Combined Hormonal Contraceptives (Triadene®)
|
Non Formulary
|
|
|
|
Combined Hormonal Contraceptives (Tri-minulet®)
|
Non Formulary
|
|
|
|
Combined Hormonal Contraceptives (Trinordiol®)
|
Non Formulary
|
|
|
|
Estradiol valerate with dienogest (Qlaira®)
|
Non Formulary
|
Not recommended. (Combined Hormonal Contraceptive.)
|
|
|
Estradiol with Nomegestrol Combined Pill (Zoely®)
|
Non Formulary
|
Not recommended. No advantage over existing options |
|
|
Ethinylestradiol / levonorgestrel phased pill (TriRegol®, Logynon®)
|
Non Formulary
|
|
|
|
Ethinylestradiol 20mcg / gestodene 75 mcg (Millinette®, Femodette®)
|
Non Formulary
|
|
|
|
Ethinylestradiol 30 mcg / levonorgestrel 150 mcg (Ovranette®)
|
Non Formulary
|
DCHFT: On local formulary. |
|
|
Ethinylestradiol 30mcg / desogestrel 150mcg (Gedarel®, Marvelon®)
|
Non Formulary
|
DCHFT: Marvelon® on local formulary. |
|
|
Ethinylestradiol 35 mcg / noresthisterone 1mg (Norimin®)
|
Non Formulary
|
|
|
|
Ethinylestradiol 35 mcg / noresthisterone 500mcg (Ovysmen®, Brevinor®)
|
Non Formulary
|
|
|
|
Ethinylestradiol 35 mcg / norgestimate 250 mcg
|
Non Formulary
|
|
|
|
TriNovum®
(THIS HAS NOW BEEN DISCONTINUED SEPT'16)
|
Non Formulary
|
Ethinylestradiol 35 micrograms/Norethisterone 500 micrograms x 7
Ethinylestradiol 35 micrograms/Norethisterone 750 micrograms x 7
Ethinylestradiol 35 micrograms/Norethisterone 1 mg x 7 |
|
|
| |
Key |
|
|
|
|
Cytotoxic Drug
|
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
Cancer Drugs Fund
|
|
NHS England |
|
Homecare |
|
CCG |
|
Traffic Light Status Information
|
|
|
